Welcome to ECVERY
ANATE ADULTS Tablets (amodiaquine Artesunat Artemisinin-based Combination Therapy (ACT))
ANATE ADULTS Tablets (amodiaquine Artesunat Artemisinin-based Combination Therapy (ACT))
Supplier Info
[China Supplier]
Contact Person : Mr. Peng Johnny
Tel : 86-563-2625199
Fax : 86-563-2625199
Product Detail
Artemisinin-based Combination Therapy (ACT) antimalarial in 3-days regimen recommended by WHO.

Brand name: ANATE®

IDENTIFICATION OF MEDICINE :                       

Pharmaceutical form and presentations:

·Pack of 1blister contains 12 tablets:

ANATE:adult (14yeas and above )

6 tablets of amodiaquine base……300mg

6 tablets of Artesunat……………  100mg

·Pack of 1 blister contains 6 tablets:

ANATE:junior (7 to 13 years )

3 tablets of amodiaquine base……300mg

3 tablets of Artesunat……………100mg

·Pack of 6

ANATE sachets: Children (1 to 6 years)

3 sachets of amodiaquine base……150mg

3 sachets of Artesunat……………50mg

ANATE sachets: Children (Below 1 year)

3 sachets of amodiaquine base……75mg

3 sachets of Artesunat……………25mg

THERAPEUTIC CLASS:Antimalarial

DAY1

DAY2

DAY3

Adults

(14years and above )

2tablets Amodiaquine

2tablets Artesunat

2tablets Amodiaquine

2tablets Artesunat

2tablets Amodiaquine

2tablets Artesunat

Junior

(7 to 13 years ) 

1tablet Amodiaquine

1tablet Artesunat

1tablet Amodiaquine

1tablet Artesunat

1tablet Amodiaquine

1tablet Artesunat

Children

(1 to 6 years)

1sachet Amodiaquine 150mg

1sachet Artesunat 50mg 

1sachet Amodiaquine 150mg

1sachet Artesunat 50mg 

1sachet Amodiaquine 150mg

1sachet Artesunat 50mg 

Pediatric

(Below 1 year)

1sachet Amodiaquine 75mg

1sachet Artesunat 25mg 

1sachet Amodiaquine 75mg

1sachet Artesunat 25mg

1sachet Amodiaquine 75mg

1sachet Artesunat 25mg

ANATE ADULTS Tablets (amodiaquine Artesunat Artemisinin-based Combination Therapy (ACT))

Ads by Google

About Us | Contact Us | Help | Terms & Conditions
Hot Products: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9
Copyright Notice @ 2008-2022 ECVERY Limited and/or its subsidiaries and licensors. All rights reserved.